LUND, Sweden, Dec. 11, 2020 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia"), a near-commercial stage diagnostics
company developing ground-breaking antibody-based multiplex
microarray technology platform called IMMray™ for the early
detection of cancer, today announced that the company will be
hosting the third webinar in the series on IMMray™ PanCan-d,
Immunovia's test for early detection of pancreatic cancer. This
third webinar will cover IMMray™
PanCan-d verification study results and its clinical use
including feedback from experts in pancreatic cancer and pancreatic
diseases.
Event Details: Webinar No. 3: Immunovia's IMMray™
PanCan-d Webinar Series Verification Study and Clinical Use
Date and Time: December 17,
2020 at 15:00 CET
Moderator for the Webinar is CEO Patrik Dahlen
Presenters: Thomas King, MD, PhD, Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia
Immediately after the webinar, the Immunovia team will host a
live Q&A session.
Webinar login and access details will be released on
Monday Dec 14, 2020.
About the presenters:
Dr. Thomas King, Medical
Director, Immunovia
Dr. King is a board-certified MD Pathologist with a PhD in
Molecular Biology also from Washington
University in St. Louis.
Dr. King also has extensive experience as a Laboratory Director in
hospital, academic and corporate settings in New England. He has
deep expertise in laboratory administration and automation,
surgical pathology, and molecular pathology and is currently an
Adjunct Associate Professor in the School of Health Professions,
Rutgers University.
Dr. Linda Mellby, VP Research
& Development, Immunovia
Dr. Mellby received her PhD in Immunotechnology from the
Department of Immunotechnology within CREATE Health Translational
Cancer Center, Lund University,
and a MSc in Chemistry Engineering. Mellby has 15+ years of
experience in recombinant antibody microarray technology,
Immunovia's IMMray™ platform. Additionally, she has
deep knowledge on platform features, technology development, as
well as, clinical applications within oncoproteomics and
autoimmunity.
Dr. Laura Chirica, Chief
Commercial Officer, Immunovia
Dr. Chirica received her PhD in Biochemistry from Umeå
University, Sweden, and a MSc in
Biochemistry and a BSc in Biotechnology. With more than 15+ years
of experiences in leading commercial positions within the life
science and diagnostics industry, Dr. Chirica contributes with
extensive experience in business, organization and strategic
development, sales, strategic and tactical marketing, product
management and product support. She has a track record of leading
and restructuring international sales and marketing organizations,
driving business development, champion integration of acquired
companies as well as developing branding and market communication
platforms.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
groundbreaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-third-webinar-in-the-series-on-immray--pancan-d--verification-study-and-clinical,c3253308
The following files are available for download:
https://mb.cision.com/Main/13121/3253308/1347348.pdf
|
Press release
(PDF)
|